Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Loviride Collaborative Study Group.
Staszewski
S
S
Johann Wolfgang Goethe Universität, Frankfurt, Germany.
Miller
V
V
Kober
A
A
Colebunders
R
R
Vandercam
B
B
Delescluse
J
J
Clumeck
N
N
Van Wanzeele
F
F
De Brabander
M
M
De Creé
J
J
Moeremans
M
M
Andries
K
K
Boucher
C
C
Stoffels
P
P
Janssen
P A
PA
D000081:Acetamides / Q000009:adverse effects / Q000627:therapeutic use*; D000098:Acetophenones / Q000009:adverse effects / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D020128:Inhibitory Concentration 50; D016131:Lymphocyte Subsets; D008297:Male; D019798:Neopterin / Q000097:blood; D015375:Receptors, Interleukin-2 / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016312:Treatment Refusal
D000081:Acetamides; D000098:Acetophenones; D019380:Anti-HIV Agents; D015415:Biomarkers; D015375:Receptors, Interleukin-2; D018894:Reverse Transcriptase Inhibitors; C080073:loviride; D019798:Neopterin